The American Journal of Managed Care

Prophylactic Tocilizumab and Sequencing Strategies in the Bispecific Era

A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...
Healio

FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be ...
The American Journal of Managed Care

FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra

Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...
standardmedia.co.ke

Arthritis drug Actemra still not a solution to Covid-19

Please enable JavaScript to read this content. Tocilizumab an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis. [Photo: Courtesy] The long ...
clinicaladvisor.com

FDA Approves Tocilizumab Biosimilar Avtozma

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a ...
Healio

Study: Tocilizumab route does not impact aortitis remission rates in giant cell arteritis

Please provide your email address to receive an email when new articles are posted on . Subcutaneous and IV tocilizumab led to similar rates of remission and inflammatory markers in GCA-associated ...